R7E Intrinsic Valuation and Fundamental Analysis - Cybin Inc

Watchlist Manager

Watchlist

Price: 9.236 EUR 0.03% Market Closed

Market Cap: €460.8m

	Cybin Inc F:R7E	CA

Intrinsic Value

There is not enough data to reliably calculate the intrinsic value for Cybin Inc.

Do our valuations actually work? See backtest results .

Fundamental Analysis

What Cybin Does

Pharmaceuticals Health Care

In the intricate world of biotechnology, Cybin Inc. emerges as a formidable player, navigating the uncharted waters of psychedelic therapeutics. Known for its innovative approach, Cybin is focused on revolutionizing mental health treatment through the research and development of psychedelic compounds. The company's ambition is to unlock the therapeutic potential of these substances, particularly psilocybin, the active component in magic mushrooms.

Headquarters: Canada CA
Employees: 50
IPO date: Jan 5, 2018

Read the full company overview

How Cybin makes money

Cybin operates by transforming its groundbreaking research into viable commercial opportunities, thus fueling its revenue stream. The company's business model is primarily research and development-centric, relying on strategic collaborations and proprietary technological advancements to propel its clinical pipelines into the pharmaceutical marketplace. Revenue is generated through partnerships with academic institutions and contract research organizations, as well as through licensing agreements for their patented delivery systems. As Cybin continues to make strides in this nascent field, it positions itself not just as a company, but as a pioneer, boldly charting a new course in the crucial intersection of mental health and biotechnology.

View Company Overview